King Pharmaceuticals has decided to discontinue the manufacture of Kemadrin (procyclidine hydrochloride tablets). This decision is based upon many factors, including the company’s understanding of current medical therapy and the availability of alternative Parkinson’s disease treatments.

Kemadrin is indicated in the treatment of Parkinsonism including the postencephalitic, arteriosclerotic, and idiopathic types.

For more information call (800) 776-3637 or visit www.fda.gov/cder/drug/shortages/default.htm#Kemadrin.